130 related articles for article (PubMed ID: 16797329)
1. The prevention of bone fractures after liver transplantation: experience with alendronate treatment.
Atamaz F; Hepguler S; Karasu Z; Kilic M; Tokat Y
Transplant Proc; 2006 Jun; 38(5):1448-52. PubMed ID: 16797329
[TBL] [Abstract][Full Text] [Related]
2. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
Planas J; Trilla E; Raventós C; Cecchini L; Orsola A; Salvador C; Placer J; Encabo G; Morote J
BJU Int; 2009 Dec; 104(11):1637-40. PubMed ID: 19549260
[TBL] [Abstract][Full Text] [Related]
3. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
[TBL] [Abstract][Full Text] [Related]
4. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation.
Dodidou P; Bruckner T; Hosch S; Haass M; Klar E; Sauer P; Ziegler R; Leidig-Bruckner G
Osteoporos Int; 2003 Jan; 14(1):82-9. PubMed ID: 12577189
[TBL] [Abstract][Full Text] [Related]
5. Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation.
Atamaz F; Hepguler S; Akyildiz M; Karasu Z; Kilic M
Osteoporos Int; 2006; 17(6):942-9. PubMed ID: 16550299
[TBL] [Abstract][Full Text] [Related]
6. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation.
Shane E; Addesso V; Namerow PB; McMahon DJ; Lo SH; Staron RB; Zucker M; Pardi S; Maybaum S; Mancini D
N Engl J Med; 2004 Feb; 350(8):767-76. PubMed ID: 14973216
[TBL] [Abstract][Full Text] [Related]
7. Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial.
Monegal A; Guañabens N; Suárez MJ; Suárez F; Clemente G; García-González M; De la Mata M; Serrano T; Casafont F; Tome S; Barrios C; Navasa M
Transpl Int; 2009 Feb; 22(2):198-206. PubMed ID: 18796000
[TBL] [Abstract][Full Text] [Related]
8. Alendronate prevents further bone loss in renal transplant recipients.
Giannini S; D'Angelo A; Carraro G; Nobile M; Rigotti P; Bonfante L; Marchini F; Zaninotto M; Dalle Carbonare L; Sartori L; Crepaldi G
J Bone Miner Res; 2001 Nov; 16(11):2111-7. PubMed ID: 11697808
[TBL] [Abstract][Full Text] [Related]
9. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study.
Millonig G; Graziadei IW; Eichler D; Pfeiffer KP; Finkenstedt G; Muehllechner P; Koenigsrainer A; Margreiter R; Vogel W
Liver Transpl; 2005 Aug; 11(8):960-6. PubMed ID: 16035083
[TBL] [Abstract][Full Text] [Related]
10. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
[TBL] [Abstract][Full Text] [Related]
11. Alendronate for steroid-induced osteopenia in children with acute lymphoblastic leukaemia or non-Hodgkin's lymphoma: results of a pilot study.
Wiernikowski JT; Barr RD; Webber C; Guo CY; Wright M; Atkinson SA
J Oncol Pharm Pract; 2005 Jun; 11(2):51-6. PubMed ID: 16460605
[TBL] [Abstract][Full Text] [Related]
12. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
[TBL] [Abstract][Full Text] [Related]
14. Alendronate treatment in osteogenesis imperfecta.
Madenci E; Yilmaz K; Yilmaz M; Coskun Y
J Clin Rheumatol; 2006 Apr; 12(2):53-6. PubMed ID: 16601536
[TBL] [Abstract][Full Text] [Related]
15. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
Skordis N; Ioannou YS; Kyriakou A; Savva SC; Efstathiou E; Savvides I; Christou S
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():144-8. PubMed ID: 19337169
[TBL] [Abstract][Full Text] [Related]
16. Alendronate in the prevention of bone loss after a fracture of the lower leg.
van der Poest Clement E; van Engeland M; Adèr H; Roos JC; Patka P; Lips P
J Bone Miner Res; 2002 Dec; 17(12):2247-55. PubMed ID: 12469919
[TBL] [Abstract][Full Text] [Related]
17. Alendronate is effective to treat bone loss in renal transplantation recipients.
Lan G; Peng L; Xie X; Peng F; Wang Y; Yu S
Transplant Proc; 2008 Dec; 40(10):3496-8. PubMed ID: 19100422
[TBL] [Abstract][Full Text] [Related]
18. The effects of daily alendronate, daily calcitonin and alendronate every other day on bone mineral density in osteoporotic men.
Guven Z; Karadag-Saygi E; Unlu-Ozkan F; Akyuz G
Aging Male; 2007 Dec; 10(4):197-201. PubMed ID: 18033629
[TBL] [Abstract][Full Text] [Related]
19. Effect of pamidronate on bone loss after kidney transplantation: a randomized trial.
Walsh SB; Altmann P; Pattison J; Wilkie M; Yaqoob MM; Dudley C; Cockwell P; Sweny P; Banks LM; Hall-Craggs M; Noonan K; Andrews C; Cunningham J
Am J Kidney Dis; 2009 May; 53(5):856-65. PubMed ID: 19393473
[TBL] [Abstract][Full Text] [Related]
20. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M
Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
